JT001

DRUG5 trials

Sponsors

Shanghai JunTop Biosciences Co., LTD, Shanghai Vinnerna Biosciences Co., Ltd., Vigonvita Life Sciences

Conditions

COVID-19Mild to Moderate COVID-19Moderate to Severe COVID-19

Phase 2

JT001 (VV116) for the Early Treatment of COVID-19

TerminatedNCT05242042

Shanghai JunTop Biosciences Co., LTDMild to Moderate COVID-19

Start: 2022-01-28End: 2023-03-23Updated: 2023-09-22

Phase 3

Efficacy and Safety of JT001 (VV116) Compared With Favipiravir

TerminatedNCT05279235

Shanghai Vinnerna Biosciences Co., Ltd.Moderate to Severe COVID-19

Start: 2022-03-14End: 2022-12-15Updated: 2023-02-08

Efficacy and Safety of JT001 (VV116) Compared With Paxlovid

CompletedNCT05341609

Vigonvita Life SciencesCOVID-19

Start: 2022-04-04End: 2022-05-31Updated: 2022-09-21

JT001 (VV116) for the Treatment of COVID-19

CompletedNCT05582629

Shanghai Vinnerna Biosciences Co., Ltd.Mild to Moderate COVID-19

Start: 2022-10-21End: 2023-02-14Updated: 2023-06-28

Unknown Phase

A Real-World Study of JT001 for COVID-19

Active, not recruitingNCT06142201

Shanghai Vinnerna Biosciences Co., Ltd.COVID-19

Start: 2023-08-31End: 2024-12-31Updated: 2024-08-26

Related Papers

Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled study.

2023-11-2235 citations

VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19

New England Journal of Medicine2022-12-28219 citations